Loading clinical trials...
Loading clinical trials...
VALO-2: A Multicenter, Phase 3b, Open-Label Treatment Extension Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita
Conditions
Interventions
PTX-022
Locations
4
United States
Arizona Research Center
Phoenix, Arizona, United States
Stanford University
Palo Alto, California, United States
Minnesota Clinical Study Center
Fridley, Minnesota, United States
University of Utah
Murray, Utah, United States
Start Date
September 1, 2020
Primary Completion Date
June 30, 2021
Completion Date
December 15, 2022
Last Updated
August 29, 2024
NCT05643872
NCT02321423
NCT05956314
NCT01382511
Lead Sponsor
Palvella Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions